WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial

Trials

Nadia Harbeck¹  Peter Staib²  Timo Schinkoethe⁴  Ronald E Kates³  Oleg Gluz⁵  Ulrike Nitz⁵  Daniel Hofmann³ 

[1] Breast Center, Department of Obstetrics and Gynecology and CCCLMU of the University of Munich, Maistr. 11, 80337 Munich, Germany;St.-Antonius Hospital, Clinic for Hematology and Oncology, Dechant-Deckers-Str. 8, 52249 Eschweiler, Germany;West German Study Group, Ludwig-Weber-Str. 15b, 41061 Moenchengladbach, Germany;Institute for Innovation and Medicine, Caramanicostr. 9A, 85551 Munich, Kirchheim, Germany;Evangelic Bethesda Hospital, Breast Center Niederrhein, Ludwig-Weber-Str. 15, 41061 Moenchengladbach, Germany

关键词: Investigator initiated trial;    Early breast cancer;    Biomarker;    ADAPT;   

Others  :  1093216
DOI  :  10.1186/1745-6215-14-261

 received in 2013-05-17, accepted in 2013-08-07,  发布年份 2013

【 摘 要 】

Background

Adjuvant treatment decision-making based on conventional clinical/pathological and prognostic single molecular markers or genomic signatures is a therapeutic area in which over-/under-treatment are still key clinical problems even though substantial and continuous improvement of outcome has been achieved over the past decades. Response to therapy is currently not considered in the decision-making procedure.

ADAPT is one of the first new generation (neo)adjuvant trials dealing with individualization of (neo)adjuvant decision-making in early breast cancer and aims to establish early predictive surrogate markers, e.g., Ki-67, for therapy response under a short induction treatment in order to maximally individualize therapy and avoid unnecessary toxicity by ineffective treatment.

Methods/design

The prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III ADAPT trial has an innovative “umbrella” protocol design. The “umbrella” is common for all patients, consisting of dynamic testing of early therapy response. ADAPT will recruit 4,936 patients according to their respective breast cancer subtype in four distinct sub-trials at 80 trial sites in Germany; 4,000 patients with hormone receptor positive (HR+) and HER2 negative disease will be included in the ADAPT HR+/HER2- sub-trial, where treatment decision is based on risk assessment and therapy response to induction therapy, and 380 patients will be included in ADAPT HER2+/HR+. A further 220 patients will be included in ADAPT HER2+/HR- and 336 patients will be recruited for ADAPT Triple Negative. These three sub-trials focus on identification of early surrogate markers for therapy success in the neoadjuvant setting. Patients will be allocated to the respective sub-trial according to the result of their diagnostic core biopsy, as reported by local/central pathology for HR and HER2 status.

Discussion

Recent trials, such as the GeparTrio, have shown that response-guided therapy using clinical response may improve outcome. For chemotherapy or HER2-targeted treatment, pathologic complete response in a neoadjuvant setting is an excellent predictor of outcome. For endocrine therapy, response to short induction treatment – as defined by decrease in tumor cell proliferation – strongly correlates with outcome. ADAPT now aims to combine static prognostic and dynamic predictive markers, focusing not just on single therapeutic targets, but also on general markers of proliferation and cell death. Biomarker analysis will help to optimize selection of subtype-specific treatment.

Trial registration

ClinicalTrials.gov: ADAPT Umbrella: NCT01781338; ADAPT HR+/HER2-: NCT01779206; ADAPT HER2+/HR+: NCT01745965; ADAPT HER2+/HR-: NCT01817452; ADAPT TN:NCT01815242.

【 授权许可】

   
2013 Hofmann et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Al-Allak A, Lewis PD, Bertelli G: Decision-making tools to assist prognosis and treatment choices in early breast cancer: a review. Expert Rev Anticancer Ther 2012, 12:1033-1043.
• [2]Kreipe HH, Ahrens P, Christgen M, Lehmann U, Länger F: Beyond staging, typing and grading. New challenges in breast cancer pathology. Pathologe 2010, 31(1):54-59.
• [3]Goncalves R, Bose R: Using multigene tests to select treatment for early-stage breast cancer. J Natl Compr Canc Netw 2013, 11(2):174-182.
• [4]Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C: Ten-year analysis of the prospective multicenter Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 2013, 49(8):1825-1835.
• [5]Zujewski JA, Kamin L: Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol 2008, 4(5):603-610.
• [6]Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F: The EORTC 10041/BIG 03–04 MINDACT trial is feasible: Results of the pilot phase. European J Cancer 2011, 47(18):2742-2749.
• [7]Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, Meisner C, Paepke D, Schmitt M, Sweep F, von Minckwitz G, Martin PM, Jaenicke F, Thomssen C, Harbeck N: Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel. BMC Cancer 2011, 11(1):140. BioMed Central Full Text
• [8]Harbeck N, Salem M, Nitz U, Gluz O, Liedtke C: Personalized treatment of early-stage breast cancer: present concepts and future directions. Cancer Treat Rev 2010, 36:584.
• [9]Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van’t Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen Y, Giri D, Au A, Hylton N: Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2012, 132(3):1049-1062.
• [10]Bae YK, Gong G, Kang J, Lee A, Cho EY, Lee JS, Suh KS, Lee DW, Jung WH: The breast pathology study group of Korean Society of Pathologists, HER2 status by standardized immunohistochemistry and silver-enhanced in situ hybridization in Korean breast cancer. J Breast Cancer 2012, 15(4):381-387.
• [11]Choritz H, Büsche G, Kreipe H: Study Group HER2 Monitor. Quality assessment of HER2 testing by monitoring of positivity rates. Virchows Arch 2011, 459(3):283-289.
• [12]Von Minckwitz G, Kaufmann M, Kuemmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Hilfrich J, Jackisch C, Gerber B, Du Bois A, Huober JB, Hanusch CA, Konecny GE, Fett W, Stickeler E, Harbeck N, Mehta K, Loibl S, Untch M: Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. J Clin Oncol 2011, 29(Suppl):abstr. 1028.
• [13]Spanheimer PM, Carr JC, Thomas A, Sugg SL, Scott-Conner CE, Liao J, Weigel RJ: The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer. Am J Surg 2013, 206(1):2-7.
• [14]Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, Baehner FL, Shak S: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010, 28:1829-1834.
• [15]Joerger M, Thürlimann B: Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert Rev Anticancer Ther 2013, 13(2):165-178.
• [16]Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R, Salter J, Detre S, Hills M, Walsh G: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007, 99:167-170.
• [17]Luporsi E, André F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, Egele C, Poulet B, Clough KB, Crouet H, Fourquet A, Lefranc JP, Mathelin C, Rouyer N, Serin D, Spielmann M, Haugh M, Chenard MP, Brain E, de Cremoux P, Bellocq JP: Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012, 132(3):895-915.
• [18]Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ: Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat 2013, 138(1):99-108.
• [19]World Medical Association: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. 2008. http://www.wma.net/e/policy/b3.htm webcite
• [20]Lim E, Winer EP: Adjuvant chemotherapy in luminal breast cancers. Breast 2011, 20(Suppl 3):128-131.
• [21]Schmitt M, Harbeck N, Brünner N, Jänicke F, Meisner C, Mühlenweg B, Jansen H, Dorn J, Nitz U, Kantelhardt EJ, Thomssen C: Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2011, 11(6):617-634.
• [22]Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL, Wolmark N: Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010, 28(10):1677-1683.
• [23]Dowsett M, Smith I, Robertson J, Robison L, Pinhel I, Johnson L, Salter J, Dunbier A, Anderson H, Ghazoui Z, Skene T, Evans A, A’Hern R, Iskender A, Wilcox M, Bliss J: Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. J Natl Cancer Inst Monogr 2011, 43:120-123.
• [24]Gluz O, Kreipe HH, Degenhardt T, Kates R, Liedtke C, Shak S, Clemens M, Markmann S, Uleer C, Augustin D, Thomssen C, Nitz U, Harbeck N, on behalf of the planB investigators: Prospective comparison of risk assessment tools in early breast cancer (Recurrence Score, uPA/PAI-1, central grade, and luminal subtypes): final correlation analysis from the phase III WSG-Plan B trial. San Antonio Breast Cancer Symposium 2011, Cancer Res 2011, 71(24 Supplement):S4-3.
• [25]Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van ‘t Veer L, Hylton N: Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012, 30(26):3242-3249.
• [26]Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S: Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res and Treat 2010, 124(1):133-140.
• [27]von Minckwitz G, Blohmer JU, Costa S, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Kümmel S, Paepke S, Schneeweiss A, Untch M, Zahm DM, Mehta K, Loibl S: S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients – Results of the GeparTrio Trial. Cancer Res 2011, 71(24 Supplement):S3-2.
• [28]von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012, 30:1796-1804.